tirzepatide cardiovascular outcomes trial results august 2025 Comparative efficacy of and glucagon-like peptide-1 receptor ESC 365 - Semaglutide is

Drugs like Ozempic, a GLP-1 agonist, are being used for looks, not their medical use

Lactic acid has been proven to help break up the keratin that clogs up hair follicles, leaving those unsightly bumps

Adverse effects such as tachycardia, infections, headaches, dizziness, nausea, vomiting, diarrhea, and dyspepsia, as well as contraindications such as a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, hypersensitivity, severe gastrointestinal diseases, renal impairment, and pregnancy have been noted

This summer, Truveta Research published its comparative effectiveness study exploring weight loss among patients taking semaglutide (Ozempic) and tirzepatide (Mounjaro) has been published in JAMA Internal Medicine

Mechanism difference Semaglutide (GLP-1 agonist): appetite regulation, satiety, improved glycemic control (New England Journal of Medicine) Tirzepatide (GLP-1/GIP agonist): broader incretin effects, robust appetite/weight effects (New England Journal of Medicine) AOD-9604: targeted fat-metabolism signaling